Navigation Links
Synvista Therapeutics Announces Availability of Haptoglobin Genotyping Technology at The Annual Scientific Sessions of the American Heart Association
Date:11/10/2008

New Data Presented at the Meeting Report the Use of Haptoglobin Typing to Predict Cardiovascular Risk, and Benefit From Tight Glycemic Control in Diabetics

MONTVALE, N.J., Nov. 10 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (Amex: SYI) today announced at the Annual Scientific Sessions of the American Heart Association, underway in New Orleans, that a new clinical test to determine haptoglobin (Hp) genotype utilizing intellectual property licensed from Synvista is now available. Knowledge of Hp genotype may help physicians to assess cardiovascular risk and guide treatment choices in their patients with diabetes. Several presentations relating to the Company's technology are being delivered during the Scientific Sessions, including one showing that older individuals with diabetes mellitus and the Hp2-2 genotype (Hp2-2 Diabetes) demonstrate a significantly higher mortality rate from cardiovascular disease than those who do not have the Hp 2-2 genotype; and another demonstrating that tight glycemic control reduces the incidence of heart attack (myocardial infarction - MI) only in Hp2-2 Diabetes.

The test, which was developed and validated by ARUP Laboratories, will be performed under a license agreement with Synvista in ARUP's CLIA-certified laboratory. In addition, Synvista has developed its own test utilizing different technology than ARUP which it intends to market as a diagnostic kit after submitting a 510(k) to, and obtaining clearance from, the U.S. Food and Drug Administration (FDA).

"We are extremely pleased that our intellectual property will have a role in making personalized medicine a reality," said Noah Berkowitz, M.D., President and CEO of Synvista Therapeutics. "We believe that the ease of use of o
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Synvista Therapeutics Posts Letter to Stockholders on Web Site
2. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
3. Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure
4. Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference
5. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
6. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
7. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
8. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
9. Synvista Therapeutics to be Featured on Wallst.net
10. Synvista Therapeutics to Present at the BIO InvestorForum 2007
11. MGuard(TM), InspireMDs Novel Coronary Stent System, was Celebrated by World Leading Interventional Cardiologists at the Transcatheter Cardiovascular Therapeutics (TCT) in Washington DC, USA, October 12-17 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... , Jan. 14, 2014 As pet owners drew up their ... of them wrote: "Take better care of my furry companion." Nowadays ... clothes and top-brand carrying cases to take the little canine or ... also feel compelled to buy some pricey toys at the pet ...
(Date:1/14/2014)... and BETHESDA, Md. , Jan. 14, ... with two institutes from the National Institutes of Health ... bringing safer, more effective treatments to patients on a ... for Advancing Translational Sciences (NCATS) and the National Eye ...
(Date:1/14/2014)... Jan. 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), ... commercializing innovative therapies addressing major unmet medical needs ... the Notice of Allowance from the United States ... RNAi compounds (sd-rxRNA®), for the treatment of fibrosis. ...
(Date:1/14/2014)... Washington, USA, and Cardiff, UK (PRWEB) January 13, 2014 ... photonics technology development leader with more than 20 years ... society for optics and photonics . Hainsey will serve ... are delighted to have Dr. Hainsey join SPIE as ...
Breaking Biology Technology:New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... 16 Exiqon today announces,the adoption of the ... the company,s commitment to expanding its business to ... guide treatment,decisions in oncology., Exiqon is pleased ... for their,clinical laboratory diagnostics business, Exiqon Diagnostics. This,progressive ...
... Oct. 16 Gaining a first-cycle,approval for a ... $640,million in incremental revenue on average, according to ... of PAREXEL International (Nasdaq: PRXL ),and leading ... device industries. According to the PAREXEL Consulting,analysis, 60 ...
... of carbon nanotubessorted by centrifuge for lengthmaterials scientists ... (NIST) have made some of the most precise ... mats of nanotubes become transparent, conducting sheets. Their ... relatively homogeneousnot overly short, but uniform in length ...
Cached Biology Technology:Exiqon A/S Announces U.S. Subsidiary Name Change From Oncotech, Inc. to Exiqon Diagnostics, Inc. 2Exiqon A/S Announces U.S. Subsidiary Name Change From Oncotech, Inc. to Exiqon Diagnostics, Inc. 3PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 2PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 3PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 4PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 5Paperwork: Buckypapers clarify electrical, optical behavior of nanotubes 2
(Date:4/23/2014)... transformed the energy landscape in the U.S., but ... among the energy industry, residents and agricultural interests ... that degraded water quality is a potential risk ... appears in the ACS journal Environmental Science ... colleagues point out that a major criticism of ...
(Date:4/23/2014)... or simply cli-fi, is a newly coined term for novels ... New research from University of Copenhagen shows how these fictions ... the potential consequences of climate change and imagine other living ... data on changes in the atmosphere; it is also a ... books we read and the films we see. And there ...
(Date:4/23/2014)... disease is the first cause of dementia and affects ... cure has yet been found. One of the reasons ... cellular mechanisms which cause alterations in nerve transmissions and ... the disease., Researchers from the Institute of Neuroscience at ... mechanism involved in memory consolidation and were able to ...
Breaking Biology News(10 mins):How to avoid water wars between 'fracking' industry and residents 2Fiction prepares us for a world changed by global warming 2Fiction prepares us for a world changed by global warming 3Loss of memory in Alzheimer's mice models reversed through gene therapy 2
... (May 23, 2008) A study led by Gregg ... Medical Center/NewYork-Presbyterian and chairman of the Cardiovascular Research Foundation, ... the direct thrombin inhibitor bivalirudin during primary angioplasty had ... rate of major bleeding, and a lower mortality rate ...
... May 22, Shire plc (LSE: SHP)(NASDAQ: SHPGY ... High Court approved,the scheme of arrangement between Shire ... The scheme, which becomes effective on 23 May ... Limited (LSE: SHP,NASDAQ: SHPGY) becoming the new holding ...
... international team of scientists surveying the waters of the ... has discovered for the first time high levels of ... raising concern for marine ecosystems from Canada to Mexico. ... research vessel, also discovered that this corrosive, acidified water ...
Cached Biology News:Findings released from 1 of the largest percutaneous coronary intervention trials ever 2Court Approves Scheme of Arrangement 2Court Approves Scheme of Arrangement 3Pacific coast turning more acidic 2Pacific coast turning more acidic 3
... When Ambion introduced the highly potent TURBO DNase ... new standard was set in DNA removal capabilities. ... DNase I that is much more efficient than ... amounts of unwanted DNA. TURBO DNase binds DNA ...
...
Lyophilized. Purity: ≥90% by electrophoresis. Reconstitute in 0.3% NaCl. Prepared from serum that has been shown by certified tests to be negative for HBsAg and for HIV and HCV antibodies. ...
Porcine Pulmonary Artery Endothelial Cells (PPAEC) (>500,000 cells)...
Biology Products: